External NordiQC Assessment Reports

GenomeMe participates in the NordiQC international quality assessment testing program for clinical IHC. Access the individual NordiQC assessment reports for each of the antibodies tested:

ANTIGEN CLONE ASSESSMENT RUN # / YEAR
BAP1 IHC761 Optimal 71 / 2024
Calretinin IHC523 Optimal 64 / 2022
CD10 IHC525 Good 66 / 2022
CD117 IHC526 Optimal 71 / 2024
CD138 IHC138 Optimal 69 / 2023
CD15 IHC527 Optimal 61 / 2021
CD20 IHC532 Optimal 71 / 2024
CD30 IHC130 Optimal 65 / 2022
CD31 IHC031 Optimal 62 / 2021
CD4 IHC535 Optimal 67 / 2023
CD5 IHC738 Optimal 69 / 2023
CD56 IHC066 Optimal 61 / 2021, 64 / 2022
CDX-2 IHC302 Good 61 / 2021
Chromogranin A IHC544 Good 67 / 2023, 70 / 2024
Cytokeratin 5/6 IHC556 Good 63 / 2021
Cytokeratin AE1/AE3 AE1/AE3 Good 71 / 2024
Cytokeratin 8/18 IHC559 Optimal 69 / 2023
Estrogen Receptor IHC423 Optimal B32 / 2021, B33 / 2022
HER2/neu IHC042 Optimal B32 / 2021, B33 / 2022
INSM1 IHC741 Good 71 / 2024
MLH1 IHC409 Optimal 67 / 2023
MSH6 IHC026 Optimal 61 / 2021
Myosin, Smooth Muscle IHC091 Optimal 66 / 2022
Napsin A IHC635 Good 66 / 2022
p40 IHC058 Good 67 / 2023
p504s IHC524 Optimal 65 / 2022
p53 IHC053 Good 70 / 2024
p63 IHC063 Good 61 / 2021
PAX-5 IHC115 Good 66 / 2022
PAX-8 IHC048 Optimal 62 / 2021, 64 / 2022
PD-L1 IHC411 Optimal C12 / 2022
PMS2 IHC422 Good 62 / 2021
PRAME IHC092 Good 68 / 2023, 70 / 2024
PSA IHC654 Optimal 69 / 2023
Progesterone Receptor IHC751 Optimal B31 / 2021, B33 / 2022
Synaptophysin IHC669 Optimal 66 / 2022
TTF1 IHC141 Optimal 68 / 2023